Ser219

Site Information
YIRKDLRsPLIAtPT SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3190885

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 4 , 5 , 6 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 2 , 4 ) , 32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 6 ) , 32Dcl3 (myeloid) ( 6 ) , macrophage-bone marrow ( 5 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 5 )

Upstream Regulation
Treatments:	insulin ( 4 ) , LPS ( 5 )

References
1	Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250 27841257 Curated Info
2	Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6 26060331 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
5	Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371 20531401 Curated Info
6	Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39 19854140 Curated Info